Vivani Medical Prepares for Global Investment Conference
Vivani Medical, Inc. (NASDAQ: VANI), a company at the forefront of biopharmaceutical innovation, is excited to announce that its CEO, Adam Mendelsohn, Ph.D., will showcase their advancements at the H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event is set to take place over three days, from September 8 to 10, bringing together a multitude of investors and industry experts.
Key Highlights of the Conference Presentation
During his presentation, Dr. Mendelsohn will provide an overview of Vivani's innovative portfolio, focusing specifically on its cutting-edge miniature, ultra-long-acting drug implants that utilize their proprietary NanoPortal™ technology. The aim of these advanced implants is to enhance adherence to medication and improve overall patient outcomes, especially among those managing chronic diseases.
Details of the Presentation
Dr. Mendelsohn's presentation will happen on September 10, during a dedicated time slot from 1:00 PM to 1:30 PM, Eastern Time. The event will be hosted at the renowned Lotte New York Palace Hotel, located in the heart of New York City, providing a beautiful backdrop for the engaging sessions.
Development of NPM-139
A significant focus of the presentation will be the anticipated advancement of NPM-139, a novel semaglutide implant. With clinical development expected to commence in 2026, pending regulatory approval, NPM-139 holds promise as an effective solution for chronic weight management in obese or overweight individuals.
Chronic Disease Management Solutions
Vivani continues to develop innovative solutions that address medication non-adherence, which affects nearly 50% of patients. By delivering drugs consistently over an extended period, Vivani's implants aim to alleviate the challenges associated with daily or weekly medication regimens. This approach includes their other notable candidates, NPM-115 and NPM-119, both targeting chronic conditions like type-2 diabetes and obesity.
About Vivani Medical, Inc.
Vivani Medical leverages its unique NanoPortal™ platform to create biopharmaceutical implants that administer medication steadily, thereby promising improved patient tolerance and adherence. The focus on evolving their product candidates, like NPM-139, demonstrates their commitment to enhancing patient care and managing complex health conditions effectively.
Company Contacts
To learn more about Vivani Medical, contact the company directly. Donald Dwyer, Chief Business Officer, can be reached at info@vivani.com or by phone at (415) 506-8462. For investor relations, reach out to Jami Taylor at investors@vivani.com.
Frequently Asked Questions
What is the purpose of the H.C. Wainwright Conference?
The conference serves as a platform for companies like Vivani Medical to connect with investors and share insights on innovations and developments in their respective fields.
Who is presenting for Vivani Medical?
CEO Adam Mendelsohn, Ph.D., will be leading the presentation at the conference.
What is the main focus of Vivani Medical's presentation?
The main focus will be on their revolutionary drug implant technology and specific product candidates such as NPM-139.
When is the presentation scheduled?
Dr. Mendelsohn's presentation is set for September 10, 2025, from 1:00 PM to 1:30 PM, Eastern Time.
How can I get in touch with Vivani Medical?
You can contact Vivani Medical through their official email at info@vivani.com for general inquiries or investors@vivani.com for investor-related questions.
